| Document |
Document Title |
|
JP7109880B2 |
To provide a novel method for simply and efficiently removing a Sn compound contained in a reaction liquid at the time of reducing an aromatic nitro compound as a starting material with stannous chloride to produce an aromatic amine comp...
|
|
JP2022530985A |
The present invention relates to the compounds of formula (IW-1) and their use in the treatment or prevention of inflammatory diseases or diseases associated with unwanted immune responses.A, RB, RC, And RDAs defined herein.
|
|
JP2022530043A |
The present disclosure discloses ionizable amine lipids and salts thereof (eg, useful for delivery of biologically active agents, eg, delivery of biologically active agents to cells for preparing engineered cells). , Its pharmaceutically...
|
|
JP7079272B2 |
The invention relates to the production of (meth)acrylic esters according to a continuous process by transesterification, and in particular to the purification of a crude reaction mixture comprising a C4-C12 (meth)acrylic ester using a d...
|
|
JP2022526213A |
Aspects of the invention are aimed at improving regulatory activity on NMDARs and structurally modified opioids (SMOs) that result in improved PK and PD parameters over existing drugs with NMDAR regulatory activity. Structural modificati...
|
|
JP2022045842A |
To provide an anti-static agent favorable in dispersibility of additives in molded articles or foreign materials derived from resins without damaging an anti-static property and seldom occurring fumes at fabrication, and to provide a pol...
|
|
JP7030690B2 |
Compounds are provided having the following structure:or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid ...
|
|
JP2022514214A |
The present disclosure discloses ionizable amine lipids and salts thereof (eg, pharmaceutically acceptable thereof) useful for the delivery of bioactive substances, eg, delivery of bioactive substances to cells for preparing engineered c...
|
|
JP7018446B2 |
This invention relates to a process for the continuous production of a (meth)acrylic ester by transesterification reaction between a C1-C4 light alkyl (meth)acrylate, with a heavy alcohol in the presence of a catalyst, characterised in t...
|
|
JP2022512736A |
The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein each R1~ R30Is independently selected from the group consisting of H and deuterium, R1~ R30At least one of them is deuterium...
|
|
JP2022512587A |
The present invention comprises at least one N-oxyl compound and at least one polymerization inhibitor other than the N-oxyl compound for preventing the decomposition of the transesterification catalyst in the method for synthesizing an ...
|
|
JP6996116B2 |
To provide a resist composition capable of producing a resist pattern having good line edge roughness.The resist composition contains a resin containing a structural unit having an acid-labile group, an acid generator, and a compound rep...
|
|
JP6993359B2 |
A lipid comprising a tri-chain cation having a cationic head group and three or more C7-24 hydrocarbyl groups for use in non-viral gene delivery systems, for example in the formation of lipopolyplex transfection vectors. Exceptionally go...
|
|
JP2022501412A |
The present disclosure discloses ionizable amine lipids and salts thereof (eg, pharmaceutically acceptable thereof) useful for delivery of bioactive agents, eg, delivery of bioactive agents to cells for preparing engineered cells. Salt) ...
|
|
JP6983910B2 |
The present invention relates to a crystal form and an amorphous form of dezocine analogue hydrochloride, and in particularly, to a crystal form of a compound represented by formula (I) and an amorphous form of a compound represented by ...
|
|
JP6977033B2 |
Provided herein is a process for preparing triaryl organoborates proceeding from alkyl or cycloalkyl boronates in the presence of an n-valent cation 1/n Kn+ to obtain organoborates of the formula 1/n Kn+R34B−—R1 (IV), where one equiv...
|
|
JP2021530541A |
In certain embodiments, the present disclosure is a method and use for treating a mammal suffering from or at risk of having a seizure-induced disease, which is disclosed herein in particular. With the step of administering the isolated ...
|
|
JP6948313B6 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
JP6957573B2 |
Compounds arc provided having the following structure:or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b , R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, R9, L1, L2, a, b, c, d and c are as defined h...
|
|
JP2021169443A |
To provide: a compound allowing derivation of a polyimide that can be used as a base resin for a photosensitive resin composition which can form a fine pattern and can achieve high resolution without impairing excellent properties such a...
|
|
JP6952911B2 |
General formula I =An organic amine ester derivative drug of 2-(α-hydroxypentyl)benzoic acid and a preparation method thereof and a use thereof are disclosed. The present disclosure particularly relates to a compound having the general ...
|
|
JP2021528474A |
The present invention relates to the general formula (I) (substituent R).1, R2And R3With respect to ester amine salts according to). The present invention further relates to a method for preparing an ester amine salt according to the gen...
|
|
JP2021167300A |
To provide a new, highly concentrated and stable, dialkyl tin oxide catalyst composition, and to provide use of the composition in the synthesis of amino alkyl (meth)acrylates by transesterification from an alkyl (meth)acrylates and an a...
|
|
JP6952113B2 |
The invention relates to a process for preparing triaryl organo borates proceeding from organoboronic esters in the presence of an n-valent cation 1/n Kn+, comprising the anhydrous workup of the reaction mixture and the use of the triary...
|
|
JP6932685B2 |
A macromolecules containing metal and a use thereof as a catalyst, said macromolecules containing metal being obtained by causing a ligand to react with a zinc compound or a cobalt compound, said ligand having an imidazole group that is ...
|
|
JP2021522196A |
The present disclosure is a pharmaceutical composition comprising a compound derived from a parent compound having a hydroxyl or amino moiety, wherein the hydroxyl in the parent compound is presented as an ester in the compound or the am...
|
|
JP6918833B2 |
The invention relates to the use of 2,6,-di-tert-butyl-4-methylphenol at a moiety of 25 to 200 ppm for stabilizing N,N-dimethylaminoethyl acrylate in respect of discoloring effects. The invention also relates to an N,N-dimethylaminoethyl...
|
|
JP6908657B2 |
The present disclosure relates to polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same.
|
|
JP6887020B2 |
[Problem]To provide a biodegradable compound having a structure decomposed in a cell, lipid particles containing the compound, and a pharmaceutical composition comprising the lipid particles.[Solution]The compound of the embodiment is re...
|
|
JP6870784B2 |
The present invention addresses the problem of providing: a polymerizable liquid crystal composition that can undergo uniform vertical alignment without a PI layer being provided, can inhibit occurrence of dropping marks or alignment irr...
|
|
JP2021507883A |
An oligomeric prodrug of etaclinic acid for the treatment of medical disorders such as glaucoma, disorders or abnormalities associated with increased intraocular pressure (IOP), disorders requiring neuroprotection, age-related macular de...
|
|
JP6812471B2 |
Provided herein are block copolymers comprising a hydrophilic polymer segment and a hydrophobic polymer segment, wherein the hydrophilic polymer segment comprises a polymer selected from the group consisting of: poly(ethylene oxide) (PEO...
|
|
JP6806089B2 |
[Problem] To provide a novel diamine that produces a film having excellent flexibility and transparency and also having low retardation characteristics. [Solution] Disclosed are: a diamine characterized by being represented by formula (1...
|
|
JP6801704B2 |
The present invention relates to (2E)-N-[2-(dimethylamino)ethyl]-2-hexadecenamide, 2-(diethylamino)ethyl (2E)-2-hexadecenoate, or pharmaceutically acceptable salts thereof. In addition to activating signal transmission via the MAP kinase...
|
|
JP6787478B2 |
Provided are: a polymerizable compound represented by formula (1), which has adequate polymerizability, a high voltage holding ratio, and high solubility in liquid-crystal compositions; a polymerizable composition comprising the compound...
|
|
JP6786775B2 |
To provide an electrochromic compound having excellent yellow color development and excellent repeated durability.The present invention provides an electrochromic compound represented by formula (I) (Rto Rindependently represent H, a hal...
|
|
JP6781202B2 |
This invention provides for a compound of formula (I):or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipid...
|
|
JP6763915B2 |
To provide an acrylate compound that is able to form a solid structure equivalent to or more than a high viscosity multifunctional acrylate while maintaining a low viscosity, and a photocurable composition, photocurable cured film and an...
|
|
JP6731912B2 |
or a pharmaceutically acceptable salt thereof, wherein RA, RB, R2 and R4 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active age...
|
|
JP6688594B2 |
To provide a liquid softening agent composition excellent in perfume retention property of a rose aroma.There is provided a liquid softening agent composition containing following (A) to (C) components. (A) tertiary or quaternary amine c...
|
|
JP2020055837A |
To provide compounds and compositions for treatment or prevention of multiple sclerosis.The invention provides an esterified compound of an aminoalcohol represented by the formula in the figure as a specific compound. Pharmaceutical comp...
|
|
JP2020011923A |
To provide a compound that has strong adhesion even in a water wet state and has excellent durability against air oxidation, and a resin composition, a coating agent, and an ink composition including the same.The present invention provid...
|
|
JP6624079B2 |
Provided is a method for producing 2-aminoethyl methacrylate hydrochloride that, according to one embodiment, includes a step (A) for reacting a ketimine compound of 2-aminoethyl methacrylate with water and hydrogen chloride and obtainin...
|
|
JP6614848B2 |
|
|
JP6607924B2 |
Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V):and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compoun...
|
|
JP6605157B2 |
Disclosed in the present invention is a Dezocine analogue, and particularly disclosed are compounds represented by formula (I), (II) and (III), a pharmaceutically acceptable salt or tautomer thereof.
|
|
JP2019189569A |
To provide a phosphine compound capable of constituting a transition metal complex excellent in reaction speed and selectivity as a catalyst.There is provided a phosphine compound represented by the formula (I). In the formula Ar represe...
|
|
JP6596483B2 |
|
|
JP6594421B2 |
Compounds arc provided having the following structure:or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b , R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, R9, L1, L2, a, b, c, d and c are as defined h...
|
|
JP6587648B2 |
The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.
|
